LOSS PER SHARE |
Loss per share is computed using the weighted average number of shares of Common Stock outstanding less the number of shares subject to repurchase.
The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share data):
Schedule of basic and diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
2023 |
|
|
2022 |
|
Numerator: |
|
|
|
|
|
|
Net loss |
|
$ |
(20,889 |
) |
|
|
(29,738 |
) |
|
|
|
|
|
|
|
|
|
Denominator - basic and diluted: |
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
74,473,741 |
|
|
|
72,335,952 |
|
|
|
|
|
|
|
|
|
|
Loss per share - basic and diluted |
|
$ |
(0.28 |
) |
|
|
(0.41 |
) |
The following table sets forth the amounts excluded from the computation of diluted net loss per share as of March 31, 2023 and 2022, because their effect was anti-dilutive.
Schedule of anti-dilutive net loss per share |
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
|
2023 |
|
|
2022 |
|
Stock options outstanding |
|
|
7,766,234 |
|
|
|
6,144,473 |
|
Non-vested shares of restricted stock |
|
|
3,830,932 |
|
|
|
3,970,385 |
|
Warrants(a)
|
|
|
21,145,000 |
|
|
|
21,145,000 |
|
Convertible notes(a)
|
|
|
9,729,163 |
|
|
|
9,729,163 |
|
(a) |
The Convertible Notes and warrants referred to in Notes 10 and 13 were also excluded on an as converted basis because their effect would have been anti-dilutive. |
|
Net loss per share is computed using the weighted average number of shares of Common Stock outstanding less the number of shares subject to repurchase.
The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share data):
Schedule of basic and diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
|
2022 |
|
|
2021 |
|
Numerator: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(85,382 |
) |
|
$ |
(70,526 |
) |
|
|
|
|
|
|
|
|
|
Denominator – basic and diluted: |
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
72,782,773 |
|
|
|
64,509,718 |
|
|
|
|
|
|
|
|
|
|
Net loss per share – basic and diluted |
|
$ |
(1.17 |
) |
|
$ |
(1.09 |
) |
The following table sets forth the amounts excluded from the computation of diluted net loss per share because their effect was anti-dilutive.
Schedule of anti-dilutive net loss per share |
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2022 |
|
|
2021 |
|
Stock options outstanding(a)
|
|
|
7,812,178 |
|
|
|
5,489,492 |
|
Non-vested RSUs and RSAs |
|
|
4,267,746 |
|
|
|
3,314,715 |
|
Warrants(b)
|
|
|
- |
|
|
|
- |
|
Convertible Notes(b)
|
|
|
- |
|
|
|
- |
|
(a) |
If the Company had reported net income, the calculation of these per share amounts would have included the dilutive effect of these Common Stock equivalents using the treasury stock method for stock options. |
(b) |
The Convertible Notes and Warrants referred to in Notes 13 and 17, respectively, were also excluded on an as converted basis because their effect would have been anti-dilutive. |
|